Core Viewpoint - BGI Genomics reported a revenue of 1.114 billion yuan for the first half of 2025, a year-on-year decrease of 7.9%, while net loss narrowed to 104 million yuan, indicating a significant improvement in financial performance due to cost reduction and efficiency enhancement strategies [2][3]. Financial Performance - Revenue for the first half of 2025 was 1.114 billion yuan, down 7.9% year-on-year [3]. - Net loss was 104 million yuan, with a significant reduction in losses of 65.28% and 37.55% for net profit attributable to shareholders and net profit excluding non-recurring items, respectively [3]. - Operating expenses (excluding financial costs) decreased by 17.04% year-on-year, optimizing the input-output ratio [3]. Business Segment Performance - The long-read sequencing business segment generated revenue of 894 million yuan, down 12.15% year-on-year [4]. - Instrument sales revenue was 298 million yuan, down 23.18%, while reagent sales were 555 million yuan, down 6.30% [4]. - The intelligent automation business segment achieved revenue of 112 million yuan, with adjusted revenue growth of 0.39% [4]. - The multi-omics business segment saw revenue of 85 million yuan, with adjusted revenue growth of 40.01% [4]. Strategic Developments - 2025 is a pivotal year for BGI Genomics' "All Long Read" strategy, with significant upgrades to its business segments, focusing on long-read sequencing (SEQ ALL), intelligent automation (GLI), and multi-omics (OMICS) [5]. - The long-read sequencing business performed exceptionally well, with over 700 sequencing instruments sold, marking a historical high and a year-on-year increase of 60.35% [5]. - R&D investment reached 324 million yuan, accounting for 29.14% of revenue, with notable product innovations including a desktop sequencer capable of producing terabyte-level data in 24 hours and an AI-integrated rapid sequencing device [5]. Market Expansion - BGI Genomics operates in over 110 countries and regions across six continents, with 13 customer experience centers and over 3,560 users served [7]. - Despite a slight revenue decline in the Americas due to geopolitical factors, revenue in Europe and Africa grew by 2.82%, and progress was made in Asia-Pacific regions with large population genomic projects [7]. - The company has established a strong presence in the domestic market, covering 1,219 hospitals, with its DNBSEQ technology accounting for 59% of clinical gene sequencing instruments approved by NMPA [7]. Future Outlook - BGI Genomics plans to continue focusing on its "All Long Read" strategy, enhancing the integration of AI and life sciences, and accelerating the clinical transformation of new products and overseas market expansion [7].